Currently, advances in HCC therapy, including an immune checkpoint molecule (e.g. PD1/PDL1) blockade strategy and adoptive transfer of immune cells [e.g. chimeric antigen receptor‐T cell (CAR‐T)] provide sturdy opportunities for HCC immunotherapy, which has been elegantly summarised by Sangro et al.3 This evidence concerns the gene CD274 and hepatocellular carcinoma.